Literature DB >> 6382609

Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse.

A M Yeager, S Brennan, C Tiffany, H W Moser, G W Santos.   

Abstract

The twitcher mouse is an animal model of galactosylceramidase deficiency (Krabbe's disease), a human sphingolipidosis. The effects of hematopoietic cell transplantation as potential enzyme replacement therapy were examined in the twitcher mouse. Survival in twitcher mice with transplants was significantly prolonged and was associated with gradual repair of demyelination in peripheral nerves. In contrast, there was no improvement in the neurodegenerative process in the central nervous system after transplantation. These observations indicate that cellular transplantation may effectively provide in vivo enzyme replacement for the peripheral manifestations of genetic storage diseases. Strategies to perturb the blood-brain barrier may be necessary for enzyme replacement to be therapeutic in diseases with central nervous system manifestations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382609     DOI: 10.1126/science.6382609

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  55 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease.

Authors:  Cynthia B Ripoll; Mette Flaat; Jessica Klopf-Eiermann; Jeanne M Fisher-Perkins; Cynthia B Trygg; Brittni A Scruggs; Marjorie L McCants; Helen Paige Leonard; Amy F Lin; Shijia Zhang; Michelle E Eagle; Xavier Alvarez; Yu Teh Li; Su Chen Li; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

3.  Effects of irradiation on the postnatal development of the brain in a genetic mouse model of globoid cell leukodystrophy.

Authors:  Francesca Galbiati; Giulia Clementi; Daniela Superchi; Maria I Givogri; Ernesto R Bongarzone
Journal:  Neurochem Res       Date:  2007-01-03       Impact factor: 3.996

4.  Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Lauren Shea; Xuntian Jiang; Daniel A Hunter; A Miguel Guzman; Adarsh S Reddy; Elizabeth Y Qin; Yedda Li; Steven J Gray; Daniel S Ory; Mark S Sands
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

Review 5.  Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations.

Authors:  Keri R Maher; Andrew M Yeager
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 6.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

7.  Bone marrow transplantation in Niemann-Pick mice.

Authors:  T Sakiyama; M Tsuda; M Owada; T Kitagawa; S Miyawaki; T Shinagawa; M Tadokoro
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

Review 8.  Animal models of lysosomal disease: an overview.

Authors:  K Suzuki; J E Månsson
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 9.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

10.  Enzyme replacement therapy for murine mucopolysaccharidosis type VII.

Authors:  M S Sands; C Vogler; J W Kyle; J H Grubb; B Levy; N Galvin; W S Sly; E H Birkenmeier
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.